{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:25:53Z","timestamp":1772166353566,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["32471290"],"award-info":[{"award-number":["32471290"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-025-01883-0","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T10:49:23Z","timestamp":1765968563000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrative analysis and experiments to explore GAS1 as a prognostic target for ovarian cancer based on angiogenesis-related genes"],"prefix":"10.1186","volume":"19","author":[{"given":"Lingyun","family":"Zhai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liya","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruqian","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qionghua","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Fei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianwei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"1883_CR1","doi-asserted-by":"crossref","unstructured":"Murphy B, Miyamoto T, Manning BS, Mirji G, Ugolini A, Kannan T, et al. Myeloid activation clears Ascites and reveals IL27-dependent regression of metastatic ovarian cancer. J Exp Med. 2024;221(12):e20231967.","DOI":"10.1084\/jem.20231967"},{"key":"1883_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ygyno.2022.11.030","volume":"169","author":"R Kahn","year":"2023","unstructured":"Kahn R, Filippova O, Gordhandas S, An A, Straubhar AM, Zivanovic O, et al. Ten-year conditional probability of survival for patients with ovarian cancer: A new metric tailored to Long-term survivors. Gynecol Oncol. 2023;169:85\u201390.","journal-title":"Gynecol Oncol"},{"key":"1883_CR3","doi-asserted-by":"crossref","unstructured":"Min Y, Park HB, Baek KH, Hwang S. Cellular functions of deubiquitinating enzymes in ovarian adenocarcinoma. Genes (Basel). 2023;14(4):886.","DOI":"10.3390\/genes14040886"},{"issue":"6","key":"1883_CR4","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/s41417-023-00590-6","volume":"30","author":"QM Nguyen","year":"2023","unstructured":"Nguyen QM, Dupre PF, Haute T, Montier T, d\u2019Arbonneau F. Suicide gene strategies applied in ovarian cancer studies. Cancer Gene Ther. 2023;30(6):812\u201321.","journal-title":"Cancer Gene Ther"},{"issue":"8","key":"1883_CR5","doi-asserted-by":"publisher","first-page":"101965","DOI":"10.1016\/j.ijgc.2025.101965","volume":"35","author":"M D\u2019Indinosante","year":"2025","unstructured":"D\u2019Indinosante M, Guidi G, Giannarelli D, Diella C, Rosati A, Oliva R, et al. Laparoscopic tumor load as an independent prognostic marker in advanced ovarian cancer: a 3-year cohort study. Int J Gynecol Cancer. 2025;35(8):101965.","journal-title":"Int J Gynecol Cancer"},{"issue":"8","key":"1883_CR6","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","volume":"34","author":"I Ray-Coquard","year":"2023","unstructured":"Ray-Coquard I, Leary A, Pignata S, Cropet C, Gonzalez-Martin A, Marth C, et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial. Ann Oncol. 2023;34(8):681\u201392.","journal-title":"Ann Oncol"},{"issue":"1","key":"1883_CR7","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1038\/s41467-024-46873-w","volume":"15","author":"L Kasikova","year":"2024","unstructured":"Kasikova L, Rakova J, Hensler M, Lanickova T, Tomankova J, Pasulka J, et al. Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer. Nat Commun. 2024;15(1):2528.","journal-title":"Nat Commun"},{"key":"1883_CR8","doi-asserted-by":"crossref","unstructured":"Bareche Y, Pommey S, Carneiro M, Buisseret L, Cousineau I, Thebault P et al. High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer. J Immunother Cancer. 2021;9(3).","DOI":"10.1136\/jitc-2020-001965"},{"issue":"8","key":"1883_CR9","doi-asserted-by":"publisher","first-page":"109165","DOI":"10.1016\/j.celrep.2021.109165","volume":"35","author":"S Olalekan","year":"2021","unstructured":"Olalekan S, Xie B, Back R, Eckart H, Basu A. Characterizing the tumor microenvironment of metastatic ovarian cancer by single-cell transcriptomics. Cell Rep. 2021;35(8):109165.","journal-title":"Cell Rep"},{"issue":"1","key":"1883_CR10","doi-asserted-by":"publisher","first-page":"6530","DOI":"10.1038\/s41598-023-30655-3","volume":"13","author":"N Guo","year":"2023","unstructured":"Guo N, Yang A, Farooq FB, Kalaria S, Moss E, DeVorkin L, et al. CD8\u2009+\u2009T cell infiltration is associated with improved survival and negatively correlates with hypoxia in clear cell ovarian cancer. Sci Rep. 2023;13(1):6530.","journal-title":"Sci Rep"},{"issue":"1","key":"1883_CR11","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1001\/jamaoncol.2020.5945","volume":"7","author":"E Zsiros","year":"2021","unstructured":"Zsiros E, Lynam S, Attwood KM, Wang C, Chilakapati S, Gomez EC, et al. Efficacy and safety of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer: A phase 2 nonrandomized clinical trial. JAMA Oncol. 2021;7(1):78\u201385.","journal-title":"JAMA Oncol"},{"issue":"3","key":"1883_CR12","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ygyno.2018.10.008","volume":"151","author":"E Hinchcliff","year":"2018","unstructured":"Hinchcliff E, Hong D, Le H, Chisholm G, Iyer R, Naing A, et al. Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials. Gynecol Oncol. 2018;151(3):407\u201313.","journal-title":"Gynecol Oncol"},{"key":"1883_CR13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ygyno.2023.09.012","volume":"178","author":"JA Ledermann","year":"2023","unstructured":"Ledermann JA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, et al. Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: exploratory analysis of KEYNOTE-100. Gynecol Oncol. 2023;178:119\u201329.","journal-title":"Gynecol Oncol"},{"issue":"7","key":"1883_CR14","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.cell.2018.03.073","volume":"173","author":"AW Zhang","year":"2018","unstructured":"Zhang AW, McPherson A, Milne K, Kroeger DR, Hamilton PT, Miranda A, et al. Interfaces of malignant and Immunologic clonal dynamics in ovarian cancer. Cell. 2018;173(7):1755\u2013e6922.","journal-title":"Cell"},{"key":"1883_CR15","doi-asserted-by":"publisher","first-page":"1111061","DOI":"10.3389\/fphar.2023.1111061","volume":"14","author":"S Zeng","year":"2023","unstructured":"Zeng S, Liu D, Yu Y, Zou L, Jin X, Liu B, et al. Efficacy and safety of PD-1\/PD-L1 inhibitors in the treatment of recurrent and refractory ovarian cancer: A systematic review and a meta-analysis. Front Pharmacol. 2023;14:1111061.","journal-title":"Front Pharmacol"},{"issue":"6","key":"1883_CR16","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1158\/2159-8290.CD-24-1366","volume":"15","author":"T Kader","year":"2025","unstructured":"Kader T, Lin JR, Hug CB, Coy S, Chen YA, de Bruijn I, et al. Multimodal Spatial profiling reveals immune suppression and microenvironment remodeling in fallopian tube precursors to High-Grade serous ovarian carcinoma. Cancer Discov. 2025;15(6):1180\u2013202.","journal-title":"Cancer Discov"},{"key":"1883_CR17","doi-asserted-by":"crossref","unstructured":"Matsushita H, Hasegawa K, Oda K, Yamamoto S, Asada K, Karasaki T, et al. Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma. J Immunother Cancer. 2020;8(1):e000375.","DOI":"10.1136\/jitc-2019-000375"},{"key":"1883_CR18","doi-asserted-by":"crossref","unstructured":"Tada Y, Togashi Y, Kotani D, Kuwata T, Sato E, Kawazoe A, et al. Targeting VEGFR2 with ramucirumab strongly impacts effector\/ activated regulatory T cells and CD8(+) T cells in the tumor microenvironment. J Immunother Cancer. 2018;6(1):106.","DOI":"10.1186\/s40425-018-0403-1"},{"issue":"2","key":"1883_CR19","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00005-017-0492-4","volume":"66","author":"M Ibanez-Vea","year":"2018","unstructured":"Ibanez-Vea M, Zuazo M, Gato M, Arasanz H, Fernandez-Hinojal G, Escors D, et al. Myeloid-Derived suppressor cells in the tumor microenvironment: current knowledge and future perspectives. Arch Immunol Ther Exp (Warsz). 2018;66(2):113\u201323.","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"12","key":"1883_CR20","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/s41590-018-0226-8","volume":"19","author":"T Bohn","year":"2018","unstructured":"Bohn T, Rapp S, Luther N, Klein M, Bruehl TJ, Kojima N, et al. Tumor immunoevasion via acidosis-dependent induction of regulatory tumor-associated macrophages. Nat Immunol. 2018;19(12):1319\u201329.","journal-title":"Nat Immunol"},{"issue":"1","key":"1883_CR21","doi-asserted-by":"publisher","first-page":"1969075","DOI":"10.1080\/2162402X.2021.1969075","volume":"10","author":"K Cao","year":"2021","unstructured":"Cao K, Zhang G, Zhang X, Yang M, Wang Y, He M, et al. Stromal infiltrating mast cells identify immunoevasive subtype high-grade serous ovarian cancer with poor prognosis and inferior immunotherapeutic response. Oncoimmunology. 2021;10(1):1969075.","journal-title":"Oncoimmunology"},{"key":"1883_CR22","doi-asserted-by":"publisher","first-page":"101665","DOI":"10.1016\/j.tranon.2023.101665","volume":"32","author":"S Qiao","year":"2023","unstructured":"Qiao S, Hou Y, Rong Q, Han B, Liu P. Tregs are involved in VEGFA\/ VASH1-related angiogenesis pathway in ovarian cancer. Transl Oncol. 2023;32:101665.","journal-title":"Transl Oncol"},{"issue":"9","key":"1883_CR23","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","volume":"52","author":"WS Lee","year":"2020","unstructured":"Lee WS, Yang H, Chon HJ, Kim C. Combination of anti-angiogenic therapy and immune checkpoint Blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp Mol Med. 2020;52(9):1475\u201385.","journal-title":"Exp Mol Med"},{"issue":"5","key":"1883_CR24","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","volume":"15","author":"KA Khan","year":"2018","unstructured":"Khan KA, Kerbel RS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol. 2018;15(5):310\u201324.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"1883_CR25","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.ccell.2022.08.014","volume":"40","author":"A Chryplewicz","year":"2022","unstructured":"Chryplewicz A, Scotton J, Tichet M, Zomer A, Shchors K, Joyce JA, et al. Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity. Cancer Cell. 2022;40(10):1111\u201327. e9.","journal-title":"Cancer Cell"},{"key":"1883_CR26","doi-asserted-by":"crossref","unstructured":"Dong X, Ren J, Amoozgar Z, Lee S, Datta M, Roberge S, et al. Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice. J Immunother Cancer. 2023;11(3):e005583.","DOI":"10.1136\/jitc-2022-005583"},{"issue":"1","key":"1883_CR27","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, et al. Pan-cancer Immunogenomic analyses reveal Genotype-Immunophenotype relationships and predictors of response to checkpoint Blockade. Cell Rep. 2017;18(1):248\u201362.","journal-title":"Cell Rep"},{"issue":"5","key":"1883_CR28","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukurnura","year":"2018","unstructured":"Fukurnura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(5):325\u201340.","journal-title":"Nat Rev Clin Oncol"},{"key":"1883_CR29","doi-asserted-by":"publisher","first-page":"104238","DOI":"10.1016\/j.critrevonc.2023.104238","volume":"194","author":"W Bao","year":"2024","unstructured":"Bao W, Li Z. Efficacy and safety of neoadjuvant chemotherapy containing anti-angiogenic drugs, immunotherapy, or PARP inhibitors for ovarian cancer. Crit Rev Oncol Hematol. 2024;194:104238.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1883_CR30","doi-asserted-by":"crossref","unstructured":"Miao D, Matulonis UA, Porter RL. Ovarian cancer therapy. Cold Spring Harb Perspect Med; 2025.","DOI":"10.1101\/cshperspect.a038232"},{"issue":"18","key":"1883_CR31","doi-asserted-by":"publisher","first-page":"5449","DOI":"10.1158\/1078-0432.CCR-18-1543","volume":"25","author":"OE Rahma","year":"2019","unstructured":"Rahma OE, Hodi FS. The intersection between tumor angiogenesis and immune suppression. Clin Cancer Res. 2019;25(18):5449\u201357.","journal-title":"Clin Cancer Res"},{"key":"1883_CR32","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.semcancer.2018.06.002","volume":"52","author":"R Missiaen","year":"2018","unstructured":"Missiaen R, Mazzone M, Bergers G. The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer. Semin Cancer Biol. 2018;52:107\u201316.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"1883_CR33","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jhep.2023.10.006","volume":"80","author":"L Zhang","year":"2024","unstructured":"Zhang L, Xu J, Zhou S, Yao F, Zhang R, You W, et al. Endothelial DGKG promotes tumor angiogenesis and immune evasion in hepatocellular carcinoma. J Hepatol. 2024;80(1):82\u201398.","journal-title":"J Hepatol"},{"key":"1883_CR34","doi-asserted-by":"publisher","first-page":"1035323","DOI":"10.3389\/fimmu.2022.1035323","volume":"13","author":"W Zheng","year":"2022","unstructured":"Zheng W, Qian C, Tang Y, Yang C, Zhou Y, Shen P, et al. Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: insight into the combination therapy of anti-angiogenesis and immune checkpoint Blockade. Front Immunol. 2022;13:1035323.","journal-title":"Front Immunol"},{"issue":"6","key":"1883_CR35","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrd.2015.17","volume":"15","author":"N Ferrara","year":"2016","unstructured":"Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15(6):385\u2013403.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"1883_CR36","first-page":"CD007930","volume":"4","author":"K Gaitskell","year":"2023","unstructured":"Gaitskell K, Rogozinska E, Platt S, Chen Y, Abd El Aziz M, Tattersall A, et al. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer. Cochrane Database Syst Rev. 2023;4(4):CD007930.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1883_CR37","doi-asserted-by":"publisher","first-page":"e1162","DOI":"10.1002\/ctm2.1162","volume":"13","author":"CW Wang","year":"2023","unstructured":"Wang CW, Lee YC, Lin YJ, Chang CC, Sai AK, Wang CH, et al. Ensemble biomarkers for guiding anti-angiogenesis therapy for ovarian cancer using deep learning. Clin Transl Med. 2023;13(1):e1162.","journal-title":"Clin Transl Med"},{"issue":"24","key":"1883_CR38","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for First-Line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288\u2013301.","journal-title":"N Engl J Med"},{"issue":"12","key":"1883_CR39","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus axitinib versus Sunitinib for advanced Renal-Cell carcinoma. N Engl J Med. 2019;380(12):1116\u201327.","journal-title":"N Engl J Med"},{"issue":"20","key":"1883_CR40","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med"},{"issue":"12","key":"1883_CR41","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1001\/jamaoncol.2019.3343","volume":"5","author":"JF Liu","year":"2019","unstructured":"Liu JF, Herold C, Gray KP, Penson RT, Horowitz N, Konstantinopoulos PA, et al. Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: A phase 2 clinical trial. JAMA Oncol. 2019;5(12):1731\u20138.","journal-title":"JAMA Oncol"},{"issue":"30","key":"1883_CR42","doi-asserted-by":"publisher","first-page":"4768","DOI":"10.1200\/JCO.23.00529","volume":"41","author":"JE Kurtz","year":"2023","unstructured":"Kurtz JE, Pujade-Lauraine E, Oaknin A, Belin L, Leitner K, Cibula D, et al. Atezolizumab combined with bevacizumab and Platinum-Based therapy for Platinum-Sensitive ovarian cancer: Placebo-Controlled randomized phase III ATALANTE\/ENGOT-ov29 trial. J Clin Oncol. 2023;41(30):4768\u201378.","journal-title":"J Clin Oncol"},{"key":"1883_CR43","doi-asserted-by":"crossref","unstructured":"Albini A, Bruno A, Noonan DM, Mortara L. Contribution to tumor angiogenesis from innate immune cells within the tumor microenvironment: implications for immunotherapy. Front Immunol. 2018;9:527.","DOI":"10.3389\/fimmu.2018.00527"},{"key":"1883_CR44","doi-asserted-by":"crossref","unstructured":"Chen X, Wang K, Jiang S, Sun H, Che X, Zhang M et al. eEF2K promotes PD-L1 stabilization through inactivating GSK3beta in melanoma. J Immunother Cancer. 2022;10(3).","DOI":"10.1136\/jitc-2021-004026"},{"key":"1883_CR45","doi-asserted-by":"crossref","unstructured":"Jiang YT, Wang CD, Zhou ST. Targeting tumor microenvironment in ovarian cancer: premise and promise. Bba-Rev Cancer. 2020;1873(2):188361.","DOI":"10.1016\/j.bbcan.2020.188361"},{"issue":"5","key":"1883_CR46","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.cell.2017.07.025","volume":"170","author":"A Jimenez-Sanchez","year":"2017","unstructured":"Jimenez-Sanchez A, Memon D, Pourpe S, Veeraraghavan H, Li YY, Vargas HA, et al. Heterogeneous Tumor-Immune microenvironments among differentially growing metastases in an ovarian cancer patient. Cell. 2017;170(5):927\u2013.","journal-title":"Cell"},{"issue":"26","key":"1883_CR47","doi-asserted-by":"publisher","first-page":"7492","DOI":"10.1016\/j.cell.2024.10.006","volume":"187","author":"G Mollaoglu","year":"2024","unstructured":"Mollaoglu G, Tepper A, Falcomata C, Potak HT, Pia L, Amabile A, et al. Ovarian cancer-derived IL-4 promotes immunotherapy resistance. Cell. 2024;187(26):7492\u2013e51022.","journal-title":"Cell"},{"key":"1883_CR48","first-page":"1","volume":"104\u2013105","author":"J Zhao","year":"2024","unstructured":"Zhao J, Wang Z, Tian Y, Ning J, Ye H. T cell exhaustion and senescence for ovarian cancer immunotherapy. Semin Cancer Biol. 2024;104\u2013105:1\u201315.","journal-title":"Semin Cancer Biol"},{"key":"1883_CR49","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/978-981-15-3266-5_9","volume":"1248","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zheng J. Functions of immune checkpoint molecules beyond immune evasion. Adv Exp Med Biol. 2020;1248:201\u201326.","journal-title":"Adv Exp Med Biol"},{"issue":"12","key":"1883_CR50","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.7150\/ijms.85114","volume":"20","author":"J Tao","year":"2023","unstructured":"Tao J, Xue C, Wang X, Chen H, Liu Q, Jiang C, et al. GAS1 promotes ferroptosis of liver cells in Acetaminophen-Induced acute liver failure. Int J Med Sci. 2023;20(12):1616\u201330.","journal-title":"Int J Med Sci"},{"issue":"1","key":"1883_CR51","doi-asserted-by":"publisher","first-page":"12477","DOI":"10.1038\/s41598-024-63346-8","volume":"14","author":"CM King","year":"2024","unstructured":"King CM, Ding W, Eshelman MA, Yochum GS. TCF7L1 regulates colorectal cancer cell migration by repressing GAS1 expression. Sci Rep. 2024;14(1):12477.","journal-title":"Sci Rep"},{"issue":"9","key":"1883_CR52","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1002\/cac2.12469","volume":"43","author":"S Chen","year":"2023","unstructured":"Chen S, Fan L, Lin Y, Qi Y, Xu C, Ge Q, et al. Bifidobacterium adolescentis orchestrates CD143(+) cancer-associated fibroblasts to suppress colorectal tumorigenesis by Wnt signaling-regulated GAS1. Cancer Commun (Lond). 2023;43(9):1027\u201347.","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"1883_CR53","doi-asserted-by":"publisher","first-page":"15286","DOI":"10.1038\/s41598-018-33306-0","volume":"8","author":"S Sarkar","year":"2018","unstructured":"Sarkar S, Poon CC, Mirzaei R, Rawji KS, Hader W, Bose P, et al. Microglia induces Gas1 expression in human brain tumor-initiating cells to reduce tumorigenecity. Sci Rep. 2018;8(1):15286.","journal-title":"Sci Rep"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01883-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-025-01883-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01883-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T12:04:51Z","timestamp":1768997091000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13048-025-01883-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1883"],"URL":"https:\/\/doi.org\/10.1186\/s13048-025-01883-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7313738\/v1","asserted-by":"object"}]},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}